Azithromycin Versus Doxycycline on Restistin Level in Periodontitis Patients With Type 2 Diabetes

Azithromycin Versus Doxycycline on Resistin Level in Periodontitis Patients With Type 2 Diabetes. A Randomized Controlled Clinical Trial

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06199440

Enrollment

Registered

2024-01-10

Start date

2022-06-01

Completion date

2023-03-30

Last updated

2024-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases, Type 2 Diabetes

Brief summary

The aim of this study is to evaluate the adjunctive effects of systemic antibiotics used in nonsurgical periodontal treatment (NSPT), compared with NSPT alone, on the periodontal clinical parameters and resistin level in diabetic patients with periodontitis, in order to identify which, one provides an additional effect to non-surgical periodontal therapy

Interventions

DRUGGroup I

First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.

DRUGGroup II

Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.

DRUGGroup III

Third group are Type 2 DM patients who received doxycycline 20mg twice/day. Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

25 Years to 50 Years

Healthy volunteers

Inclusion criteria

Patients were clinically diagnosed as having at least three site with CAL ≥ 5mm; moderate to advanced chronic periodontitis according to the criteria of American Academy of Periodontology. * Free from any other systemic conditions that affect the periodontium except for Diabetes mellitus type II. * No periodontal therapy, systemic antibiotics or non-steroidal anti-inflammatory agents during the preceding 6 months. * Non-smokers. * Non-pregnant.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Primary Outcome	3 months	Improvements in clinical parameters of periodontitis including Gingival Index, Probing Depth and Clinical Attachment Level

Secondary

Measure	Time frame	Description
Secondary Outcome	3 months	Improved resistin level

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026